INOVIO and Advaccine Announce First Dosing of Subject in Phase...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire-AsiaNet/ -- -- Dosing marks a key milestone for INO-4800 in China and its secondPhase 2 clinical trial globallyINOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect peop...
Authors: LATEST ASIANET NEWS RELEASES